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LABORATORY INVESTIGATION
Platelet activating factor inhibits Cl and K transport in the
medullary thick ascending limb
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Platelet activating factor inhibits Cl and K transport in the medullary
thick ascending limb. Since the kidney medulla was reported to generate
platelet activating factor (PAF), we investigated a possible effect of this
agent on the reabsorptive function of in vitro microperfused medullary
thick ascending limbs from mouse kidney (mTAL). PAF, l0 M in the
bath, significantly decreased the net chloride flux (JCI) from 48.8 7.1
to 27.4 5.7 pmol/min. This effect was reversible, blocked by the
antagonist BN 50730, and not reproduced by the inactive metabolite
lyso-PAF. PAF inhibited the transepithelial potential difference with a
threshold at lO M. In the presence of isoproterenol, the PAF-induced
decrease of JCI was not significantly different from that observed in
basal conditions; moreover, PAF did not modify the adenylate cyclase
activity in isolated mTALs, either in basal condition or under stimula-
tion by isoproterenol. The effect of PAF on JC1 was not prevented by
mepacrine, NDGA associated with proadifen, or adenosine desami-
nase. When the apical Na-K-2C1 cotransport was blocked by furo-
semide or bumetanide, a net K secretion occurred (—1.1 0.2
pmol/min), which was significantly decreased by PAF (—0.06 0.3
pmol/min). Moreover, it was verified on isolated mTALs that PAF did
not modify the Na,K-ATPase activity. It is concluded that PAF inhibits
the reabsorptive function of the mTAL, as indicated by the decrease of
Cl reabsorption and K secretion. This effect could not be accounted for
by adenosine or arachidonic acid metabolite action, and was not
mediated by an inhibition of the adenylate cyclase activity.
Platelet activating factor (PAF, l-0-akyl-2-0-acetyl-SN-glyc-
ero-3 phosphocholine), a mediator of anaphylactic shock and
inflammation, was shown to be produced by a wide variety of
cells [reviewed in 1]. The generation of PAF by the mesangial
cells of the glomeruli [2] and by the renal medulla cells [31
suggested a paracrine action of this agent. As far as the effect of
PAF on renal function was concerned, numerous studies [re-
viewed in 1] reported that PAF induced a decline of the
glomerular filtration rate, an effect that might partly result from
mesangial cells contraction, thromboxane A2 production,
and/or decrease in blood pressure [4, 5]. Furthermore, PAF was
proposed as a potential mediator in the pathogenesis of glomer-
ulonephritis [6].
Only few data are available about a possible direct tubular
effect of PAF [7, 8]. The studies, moreover, were performed in
vivo, thus the decrease in urinary flow rate and sodium excre-
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tion [8] as well as of calcium and magnesium excretion [7]
observed during PAF infusion could not be definitely dissoci-
ated from hemodynamic effects. Nevertheless, a direct action
of PAF on the collecting tubule was recently suggested by the
report of a PAF induced increase in cytosolic free calcium
concentration in cultured inner medullary collecting duct cells
[91.
The aim of the present work was to investigate a possible
effect of PAF on the reabsorptive function of the medullary
thick ascending limb of Henle's loop (mTAL), especially on net
chloride reabsorption and net potassium secretion, by the in
vitro microperfusion technique. The main results indicated that:
i) PAF decreased chloride reabsorption, potassium secretion,
and the transepithelial potential difference (PDt); ii) PAF did
not act by inhibiting the adenylate cyclase activity; iii) these
effects were not likely to be mediated by arachidonic acid
metabolite or adenosine. In addition to prostaglandin E2 (PGE2)
[10] PAF thus represents an inhibiting agent of the mTAL
function.
Methods
Microperfusion experiments
mTALs were microperfused in vitro following the technique
first described by Burg et al jill] and detailed elsewhere [12].
Briefly, male Swiss White mice, 18 to 25 g body wt, were killed
by cervical dislocation and exsanguinated. Coronal slices were
then cut from both kidneys and were immediately immersed in
a cold perfusing solution (see Composition infra) added to 0.4%
bovine serum albumin (Sigma Chemical Co., St. Louis, Mis-
souri, USA). mTALs (length = 563 34 pm) were harvested
from the inner stripe of the outer medulla. The segments were
then transferred to a Lucite chamber (1.5 ml) in which the bath
was continuously flowing at 5 ml/min. Bath temperature was
thermostatically maintained at 37 0.5°C (YSI probe, Yellow
Springs Instruments Co., Yellow Springs, Ohio, USA). When
the tubular fluid was collected (all series except IV; see Infra),
the tubules were perfused at a rate of about 3 nl/min. When the
transepithelial potential difference (PDt) was recorded and no
tubular fluid collected (series IV), the tubular flow rate was
more than 10 nI/mm. In this condition, it was supposed that no
sodium chloride gradient between the bath and the perfusate
occurred and consequently that no dilution potential was gen-
erated.
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Each collection experiment lasted two hours. Unless other-
wise mentioned, a 30-minute experimental period was preceded
by a 30-minute control period and followed by a 30-minute
recovery period. Ten minutes were allowed for equilibration
between the control and the experimental periods as well as
between the experimental and recovery periods. The luminal
fluid was collected every 10 minutes so that three samples per
period of 30 minutes were collected.
Nine series of experiments were performed:
Series I (N = 12). PAF (Eurobio, Paris, France) was added to
the bath in the experimental period, at the final concentration of
iO M. The solvent (chloroform) was present in the bath
throughout the experiment (1/10,000 vollvol).
Series II (N = 5). The protocol was identical to series I. In
addition, a specific antagonist of PAP, BN 50730 (gift from
Beaufour, Les Ulis, France), was present in the bath at the final
concentration of 2. l0_6 M throughout the experiment.
Series III (N = 6). Lyso-PAF (Eurobio, Paris, France) was
added to the bath in the experimental period at the final
concentration of lO M.
Series IV (N = 8). PAF at final concentrations ranging from
10_li to 10_6 M was added to the bath. On each tubule, two to
four PAF concentrations were tested. For each tested concen-
tration, the control, experimental, and recovery periods lasted
about 10 minutes, during which the PDt was continuously
recorded.
Series V (N = 5). The protocol was the same as in series I. In
addition, mepacrine (Sigma), a phospholipase A2 inhibitor, was
present in the bath at the final concentration of 6.10—6 M
throughout the experiment.
Series VI (N = 5). Nordihydroguaiaretic acid (NDGA,
Sigma) and proadifen (Eurobio), inhibitors of lipooxygenase
and cytochrome P450 monooxygenase, respectively, were both
added to the bath at the final concentration of 106 M through-
out the experiment. Two tubules were used as the time control.
In three tubules, PAF was added during the experimental
period as in series I. No recovery period was performed in this
series.
Series VII (N = 7). The protocol was identical to series I,
however, in order to prevent a possible effect of endogenous
adenosine, adenosine desaminase (ADA, Boehringer, Mann-
heim, Germany) was present in the bath at the final concentra-
tion of 2.5 mg/liter throughout the experiment. Moreover, in
one tubule, adenosine desaminase was present in the perfusate
at the same concentration as in the bath, and in two tubules, a
specific A1 adenosine antagonist, 1 ,3-Dipropyl-8-(2-amino-4-
chlorophenyl) xanthine (PACPX, Research Biochemicals Inc.,
Natick, Massachusetts, USA), was present in the bath at the
final concentration of l0— M, as well.
Series VIII (N = 5). The protocol was as in series I; in
addition, isoproterenol (Isuprel©) was present in the bath at the
final concentration of i0 M throughout the experiment.
Series IX (N = 6). As in series I. In addition, tubules were
perfused with furosemide (Lasilix©, N = 2) at the final concen-
tration of iO M, or bumetanide (gift of Hoffman LaRoche
Laboratory, Basel, Switzerland, N = 4) at the final concentra-
tion of 6.10—6 M, throughout the experiment.
The composition of the perfusing solution was as follows (in
mM): NaCl 147, K,HPO4 2.4, NaH2PO4 0.6, MgCl2 1, CaCI2 1,
urea 10, N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid
(HEPES) 5. The composition of the bathing solution was similar
except for lower NaC1 concentration, 142 m, because of the
addition of glucose 5 m and Na acetate 5 mi. All solutions
were adjusted to 300 mOsmol/kg H20 with urea and to pH 7.38
to 7.42.
The PDt was recorded (Keithley Instruments, Cleveland,
Ohio, USA) between two calomel electrodes connected to the
bath and perfusate by 5% agar bridges in 0.9% NaCl. The
volumes of the collected samples were measured with a cali-
brated constriction pipette, and the flow rate of perfusate was
calculated assuming that water reabsorption was negligible in
the mouse mTAL [131. In the samples and perfusate, potassium
and chloride concentrations were determined by ultramicron
emission spectrophotometry [14] and microelectrometric titra-
tion [15J, respectively. The results were expressed as net fluxes
for the whole segment, calculated by multiplying the tubular
flow rate by the concentration difference between the perfused
and the collected fluid. Since it was reported that, in the mouse
mTAL, chloride reabsorption decreases [16] as the luminal
chloride concentration decreases, the net fluxes could not be
considered as proportional to tubular length and therefore were
not monitored by the tubular length.
The results from each period were pooled and considered as
one point. The data were expressed as means SE. To calculate
the inhibition of the net chloride flux (JC1) as the percentage of
the control value, it was verified that a linear relationship
existed between JC1 in the experimental period and JC1 in the
nonexperimental periods (mean of control and recovery val-
ues). For series I, II, III, V, VII, and VIII, the correlation was
significant (0.01 < P < 0.001). Statistical significance was
evaluated in the same series by the paired Student's t-test, and
between the series (N = 7) by the one-way analysis of variance
followed by the least significant difference method.
Na,K-ATPase activity determination
The technique already reported for rat kidney [17] was
modified as follows: male Swiss mice were anesthetized with
pentobarbital sodium (0.5 mgllO g body wt). The left kidney was
perfused in situ via the abdominal aorta with 2 ml of incubation
solution containing (in mM) NaCl 120, KC1 5, CaC12 1, MgSO4
1, NaH2PO4 4, NAHCO3 4, glucose 5, lactate 10, pyruvate 1,
essential and nonessential amino acids 4, vitamins (vitamins for
Eagle's minimum essential medium, Eurobio) 30, and HEPES
20. Dextran 40,000 (0.3% wt/vol), collagenase (CLS II, 240
U/mg, Worthington) 0.3% wt/vol, and bovine serum albumin
0.2% wt/vol were added. The left kidney was removed and thin
pyramids were then cut out along the corticopapillary axis of
the kidney and were incubated for 15 minutes at 30°C in the
incubation solution containing 0.1% collagenase. mTALs were
microdissected from the inner stripe of the outer medulla in
incubation solution maintained at 4°C. The length of each
sample was determined by automatic image analysis.
ATPase activity was determined under Vmax conditions by a
radiochemical microassay, that is, measurement of 32P released
from (32Pa) ATP, after permeabilization of cell membranes.
ATPase activity was expressed as picomoles of inorganic
phosphate liberated per millimeter of tubule length per hour.
For each condition, ATPase was measured on four to six
replicate samples. Na,K-ATPase activity was calculated as the
.1St
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difference between the activities determined either in the pres-
ence or in the absence of Na. Results are presented as means
SE of the values from several animals. Statistical significance
was assessed by Student's t-test.
Adenylate cyclase activity determination
Adenylate cyclase activity was determined in single mTAL
tubules by use of the microassay previously described in the rat
[18]. Tubule microdissection was carried out on mice kidney as
reported above for Na,K-ATPase activity determination.
mTALs were individually incubated at 0 to 4°C for 30 minutes
in 0.5 d of a hyposmotic solution containing 0.25 ms'i EDTA, 1
mM MgCl2, 5 X l0 M GTP, I mg/mi bovine serum albumin,
and 8 mri Tris (hydroxymethyl) aminomethane, Tris HC1, pH
7.6. When necessary, isoproterenol or PAF were added to this
solution at a concentration of l0 M in the final incubate.
Samples were then submitted to a brief freezing on dry ice
before adenylate cyciase measurement was initiated by adding
2 pl of incubation medium to each of them. The composition of
this medium was adjusted to obtain the following concentra-
tions in the final incubate: cAMP 1 mrvi, EDTA 0.25 mM, MgCl2
4 mM, GTP i0 M, [32Pcr] ATP 0.30 to 0.35 mii (0.5 to 0.8
pCi/sample), phosphocreatine 20 mrvi, creatine kinase I mg/ml,
and Tris HC1 (pH 7.6) 100 mrvi. After a 30 minute incubation at
30°C, the reaction was stopped by adding 150 d of a solution
containing 3.3 mrvi ATP, 5 mtvt cAMP, 50 mM Tris HCI, and
tracer amounts of [3H]-cAMP for recovery calculations. The
[32P]-cAMP formed was separated from other labeled nucleo-
tides by double filtration through Dowex and aluminium oxide
columns, and the radioactivity present in the eluate was
counted by liquid scintillation.
Adenylate cyclase activity was calculated as femtomoles of
cAMP formed per 30 minutes of incubation period per millime-
ter tubular length. For each experimental condition, adenylate
cyclase was determined on four to six replicate samples.
Results were calculated as means SE of the value from several
animals. Statistical analysis was performed by Student's t-test.
Results
Effect of PAF on the net chloride reabsorption and on PDt
The results obtained in series I (Fig. 1) showed that PAF
significantly decreased the net chloride flux (JC1) from 48.8
7.1 pmol/min to 27.4 5.7 pmol/min (P < 0.001). This effect
was partly reversible since JC1 returned to 33.4 7.9 pmol/min
(P < 0.05) after removal of the PAF. This effect did not result
from a decrease of the tubular flow rate since the flow rate was
fairly constant throughout the experiment (V, ni mm: 3.08
0.44, 2.94 0.47, 2.73 0.51, in control, experimental, and
recovery periods, respectively, NS vs. the preceding period).
The effect of PAF on JCI was completely blocked by BN 50730
(series II, Fig. 1). Moreover, it was not reproduced by lyso-
PAF (series III), an inactive metabolite of PAF, since JCI was
decreased by 6.4 4.0% (nonsignificantly different from zero)
versus 36.8 3.8% in the presence of PAF (P < 0.001).
However, the progressive decrease with time of JC1 observed in
the series III accounted partly for the incomplete reversibility
of JC1 after PAF removal (series I).
The effect of PAF at different concentrations was tested on
PDt (series IV, Fig. 2). The mean control value of PDt for all the
tested tubules was 6.9 1.3 mV. PAF inhibited PDt with a
threshold at i0 M (PDt: 90.4 1.9% of the control value, P <
0.01). At 106 M, the inhibition of PDt was significantly higher
(P < 0.01) than at io— M, the concentration used in this study.
To investigate a possible mediation of the PAF effect by
arachidonic acid metabolites or by adenosine, the inhibitory
effect of PAF on JCI was evaluated in the presence of mepa-
crine, a phospholipase A2 inhibitor (series V), and under
conditions preventing a possible adenosine accumulation and/or
action (ADA, series VII).
Comparison between the series (Fig. 3) indicated that the
percentage of inhibition of JC1: 1) was not significantly different
between the series PAF (series I), PAF plus mepacrine (series
V), and PAF plus ADA (series VII); and 2) was significantly
higher in the presence of PAF (series I, V, and VII) than in the
presence of lyso-PAF (series III) and BN 50730 (series II).
Moreover, in the presence of NDGA and proadifen (series VI),
Fig. 1. Effect of PAF on chloride reabsorption (JC1) in the absence anc
in the presence of BN 50730. BN 50730, 2 x 106 M, was present during
all the periods. C: control period; E: experimental period (PAF iO M,
series I and II); R: recovery period. ', ** Significantly different from the
preceding period; * P < 0,05, ** P <0.001. The control periods in the
absence and in the presence of BN 50730 do not differ significantly.
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Fig. 2. inhibition of transepithelial potential difference (PDt) by df-
ferent concentrations of PAF. Abscissa: PAF concentration (log scale);
ordinate: PDt, expressed as the percentage of the control value for each
tubule. (N): number of determinations.
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Fig. 3. inhibition of chloride reabsorption (JCI) in the presence of
lyso-PAF 10 M(series III), PAF 10 MplusBN 50730 (2 X 10-6 M,
series Ii), PAF io— M (series I), PAF 1O M plus adenosine desami-
nase (ADA, 2.5 mg/liter, series VII), and PAF iO M plus mepacrine
(MEPA, 6 x 10—6 M, series V). Ordinate: percentage of inhibition of JCI
by comparison with the control value. For each tubule, the control
value was the mean of the control and recovery periods. * Significantly
different from lyso-PAF and BN 50730 (P < 0.001).
the decrease of JCI was 10.0 1.3 pmol/min in the presence of
PAF while it was only 4.3 0.4 pmollmin in the absence of
PAF.
The effect of PAF on JC1 was investigated when adenylate-
cyclase activity was stimulated by isoproterenol (series VIII).
As already shown in our laboratory [12], isoproterenol signifi-
cantly increased JCI: In the control period (Table 1), JC1 was
significantly higher than in the absence of isoproterenol (744
10.5 vs. 48.8 7.1 pmollmin, series VIII vs. series I, P <0.01).
In the presence of isoproterenol, PAF induced a significant
decrease of JC1 (Table 1). The decrease of JC1 was not signifi-
cantly different from that obtained in the absence of isoproter-
enol (26.5 4.0 vs. 21.4 2.9 pmol/min, series VIII vs. series
I, NS). Moreover, when adenylate cyclase activity was deter-
mined on isolated mTALs, the results indicated that PAF did
not significantly modify the enzyme activity, either in basal
condition or in the presence of isoproterenol (Table 2).
Effect of PAF on the net potassium secretion
Before any addition of a Na-K-2C1 cotransport blocker (se-
ries IX), the chloride concentration difference between the
perfused and the collected fluid (zCl) was 17.8 2.2 mi, a
value not significantly different from that observed in the
control period of series I (20.4 4.2 mM) for similar tubular
flow rates (3.08 0.4 vs. 3.58 0.3 nllmin, series I vs. series
IX, NS), Administration of furosemide or bumetanide at the
luminal side resulted in a fall of iCl to 1.0 0.8 m, as well as
in an abolition of PDt from 5.8 0.9 mV to 0.4 0.2 mV
(results from the first control sample). In this condition, a net
significant K secretion (JK) occurred in the control period
(—1.14 0.21 pmol/min). In the presence of PAF (Fig. 4), JK
was significantly decreased to a value not different from zero
(—0.06 0.28 pmol/min, P < 0.01 vs. control period). After
removal of PAF (recovery period), a net potassium secretion
resumed (—0.62 0.16 pmollmin, significantly different from
zero, P < 0.01).
Table 1. Effect of PAF on Cl reabsorption by mTALs in the
presence of isoproterenol
V iXCI JC1
Period nI/mm m pmoles/min
Control (isoproterenol) 3.1 0.6 26.9 5.3 74.4 10.5
Experimental 3.1 0.5 17.0 43 47.7 95a
(isoproterenol + PAF)
Recovery (isoproterenol) 3.0 0.5 20.6 4.2 56.6 9.6a.c
Values are means SE. Abbreviations are: V, tubular flow rate; Cl,
chloride concentration difference between the perfused and the col-
lected fluid; JCI, net chloride flux. Difference in Cl between the
recovery and the experimental periods was at the limit of significance
(t = 2.4).
a,b Significantly different from the control period, a P < 0.05; b p <
0.01
Significantly different from the experimental period, P < 0.05
Table 2. Effect of PAF on isoproterenol-sensitive adenylate cyclase
activity in mTALs
Adenylate cyclase
fmol. cAMP/30 mm mm
Baseline
PAF
15.8
13.6
0.2
1.2
ISO 89.2 lO.9a
ISO + PAF 87.6 5.6a
Values are means s. For each condition, 5 tubule samples were
obtained from 5 mice. Abbreviations are ISO, isoproterenol (10 M);
ISO + PAF, isoproterenol (10 M) plus platelet-activating factor(l0 M).
a Significantly different from basal value, P < 0.001
The basolateral entry of K was estimated by the determina-
tion of the Na,K-ATPase activity on isolated mTALs. PAF
i0 M did not significantly modify the enzymatic activity
(Table 3), this absence of effect persisted independent of the
preincubation time.
Discussion
The present study represents the first demonstration of a
direct tubular effect of PAF. The data showed that, in addition
to PGE2 [10], PAF could inhibit the reabsorptive function of the
mTAL since it decreased chloride reabsorption, potassium
secretion, and, consequently, PDt. Moreover, the results Sug-
gest that neither adenosine or arachidonic acid metabolite could
account for the PAF effects and showed that, at variance with
what was reported for PGE2 [19, 20], the effect of PAF was not
related to an inhibition of adenylate cyclase activity.
Direct effect of PAF
The present data showed that, in the mTAL, PAF decreased
PDt as the consequence of the decrease of JCI and JK (see
below). In the thick ascending limb, PDt could also be de-
creased either by adenosine, as recently shown in the cortical
part [21], or by PGE2 in the medullary part [10]. The present
results indicated that adenosine could not entirely account for
the inhibitory effect of PAF on JCI, since that effect persisted
when adenosine accumulation and/or action on the mTAL was
prevented by adenosine desaminase and an adenosine antago-
nist, the PACPX. As far as PGE2 was concerned, the question
of its possible role as a mediator of PAF was raised since PAF
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Fig. 4. Effect of PAF on individual net fluxes of potassium (JK). C:
control period; E: experimental period (PAF lO M, series IX); R:
recovery period, Negative values indicate a net secretion.
was reported to stimulate POE2 synthesis in the glomeruli [4].
Two lines of evidences allow us to reject this hypothesis: i) In
the thick ascending limb of Henle's loop, undetectable levels of
PGE2 are produced [22, 23]; ii) the blockade of arachidonic acid
production by mepacrine, a phospholipase A2 inhibitor, failed
to modify the effect of PAF on JC1. Moreover, provided that
phospholipase A2, lipooxygenase, and cytochrome P450 mono-
oxygenase were completely blocked in the present conditions,
the fact that the presence of NDGA plus proadifen did not
prevent the effect of PAF suggests that no arachidonic acid
metabolite was involved.
PAF and cyclic AMP
When adenylate cyclase was stimulated by isoproterenol,
PAF exerted on JCI an effect that was similar to that observed
in basal conditions. Moreover, the data indicated that PAF had
no effect on adenylate cyclase activity neither in basal condi-
tions or when stimulated by isoproterenol [12], thus the mech-
anism of PAF action could be different from that described for
PGE2. In the mTAL, indeed, PGE2, which was shown to inhibit
cyclic AMP synthesis [19, 20], displayed a pattern of action
different from that reported here for PAF: POE2 failed to exert
any effect on cyclic AMP content [19] as well as on PDt [10] in
basal conditions, but decreased PDt and cAMP production
when adenylate cyclase was hormonally stimulated,
Cellular mechanisms for the PAF effect on the mTAL
function
The results presented here show that PAF decreased the net
chloride reabsorption and the net potassium secretion in the
mTAL. According to the model for sodium chloride reabsorp-
tion in this segment [24, 25] the transepithelial chloride reab-
sorption is active via an apical Na-K-2C1 cotransport, while the
transepithelial sodium reabsorption is both active via the Na-
K-2Cl cotransport and passive through the shunt pathway. The
electrical driving force for the passive sodium reabsorption is a
positive luminal PDt resulting from both potassium exit through
an apical conductance and chloride exit through a basolateral
conductance. The inhibition by PAF of JCI might thus result
from either a decrease of the apical Na-K-2Cl cotransport
Table 3. Effect of PAF on the Na,K-ATPase activity in isolated
mTALs
Preincubation time
mm
Na,K-ATPase activity pmol/hr. mm
Control PAF iO M
0 5175 310
(4)
5005 322
(3)
10 4769 1053
(2)
4843 591
(3)
30 5180 640
(3)
5016 444
(3)
60 4848
(1)
4410 443
(2)
Values are means SE. (N), five tubular samples were obtained from
each mice, the number of mice is indicated in parenthesis for each
condition. PAF l0— M was added either at the time of the enzymatic
activity determination or 10 to 60 minutes before, in the incubation
medium.
activity and/or a decrease of the basolateral chloride conduc-
tance.
As far as potassium was concerned, PAF decreased its net
secretion, likely in the absence of modification of the driving
force since: i) a passive potassium transport was prevented in
zero PDt conditions; ii) the apical entry of potassium was
blocked by furosemide or bumetanide; iii) the basolateral entry
of potassium was likely unchanged since the data indicated that
the Na,K-ATPase activity was not modified in the presence of
PAF. These results are compatible with a decreased potassium
secretion resulting from a PAF-induced decrease of a potassium
conductance. Since PAF was reported to increase cytosolic
calcium concentration in many target cells [1], including the
epithelial kidney cells [26], it is attractive to speculate, as a
working hypothesis, that PAF induced the decrease in potas-
sium secretion via an inhibition of the apical calcium-inhibited
potassium channel [27].
Possible physiological relevance of the effect of PAF on the
mTAL function
The present data indicated that PAF decreased PDt at a lO—
M concentration. Several evidences suggest that this threshold
of concentration obtained in vitro is compatible with an effect of
endogenous PAF: i) In kidney homogenates, the medullary
production of PAF was reported to be about 1.5 pmol/mg
protein [3]. Assuming a concentration of 10 g protein per 100 g
of wet tissue, one can estimate a PAF concentration of about
10 M in the medulla, thus only one order of magnitude below
the concentration active in vitro. ii) The blockade by a PAF
antagonist of the PAF-induced inhibition of JCI suggested,
although it did not prove, that PAF exerted this effect via
specific receptors. iii) Regarding the well-known effect of PAF
on the contraction of the glomerular mesangial cells, Schlon-
dorff et al [4] reported a value of Kd between i0 and l0 M.
PAF was reported to be a hypotensive agent that decreased
renal blood flow, leading to a medullary hypoperfusion. In the
mTAL, Brezis et al [28] showed a high sensitivity to hypoxia
and that the resulting epithelium damages may be prevented by
inhibition of the NaCl reabsorption. We thus suggest that the
inhibitory effect of PAF on the mTAL reabsorptive function
might result in a preservation of the cell integrity of this
segment during renal injury.
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In summary, the present work showed that PAF decreased
chloride reabsorption and potassium secretion in the mTAL.
This effect was not mediated by an inhibition of the adenylate-
cyclase activity, and likely resulted from a direct tubular effect
of PAF. The possible implication of this effect in the preserva-
tion of the tubular function during renal injury needs further
investigation.
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